CytomX Therapeutics (CTMX) Operating Leases (2019 - 2025)

CytomX Therapeutics' Operating Leases history runs 7 years deep, the most recent figure standing at $1.4 million for Q2 2025.

• Quarterly Operating Leases fell 79.06% year-over-year to $1.4 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $1.4 million (down 79.06% YoY) and the FY2024 annual result came in at $4.2 million, down 54.82% from the prior year.
• Operating Leases was $1.4 million for Q2 2025 at CytomX Therapeutics, down from $2.9 million in the prior quarter.
• Across five years, Operating Leases topped out at $20.8 million in Q1 2021 and bottomed at $1.4 million in Q2 2025.
• A 5-year average of $11.9 million and a median of $12.3 million in 2023 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2021 — Operating Leases declined 13.68% — and 2025, when it tumbled 79.06%.
• CytomX Therapeutics' Operating Leases stood at $18.1 million in 2021, then slipped by 22.6% to $14.0 million in 2022, then tumbled by 32.84% to $9.4 million in 2023, then slumped by 54.82% to $4.2 million in 2024, then slumped by 65.99% to $1.4 million in 2025.
• Business Quant data shows CTMX's Operating Leases at $1.4 million in Q2 2025, $2.9 million in Q1 2025, and $4.2 million in Q4 2024.